前列地尔联合贝那普利治疗2型糖尿病肾病蛋白尿的疗效观察

摘要

ObjectiveTo explore the clinical effect of alprostadil combined with benazepril on type 2 diabetic nephropathy proteinuria.Methods 78 patients of type 2 diabetic nephropathy were randomly divided into study group and control group,39 cases each,the control group were treated with benazepril, the study group were given alprostadil combined with benazepril.ResultsAfter treatment,24 h urinary albumin and 24 h urinary microglobulin excretion of patients had decreased significantly,the degree of reduction in the study group was significantly higher(P<0.05),the incidence of adverse events of study group was significantly lower than control group(P<0.05).Conclusion Alprostadil combined with benazepril treatment of diabetic nephropathy can significantly reduce urinary albumin content,with low incidence of adverse reactions,which can be widely used.%目的：探讨前列地尔联合贝那普利治疗2型糖尿病肾病蛋白尿的临床效果。方法78例2型糖尿病肾病患者，分为研究组和对照组各39例，对照组患者给予贝那普利治疗，研究组在给予前列地尔联合贝那普利治疗。结果治疗后两组患者24 h尿蛋白含量和24 h尿微蛋白排泄量都发生了降低，研究组降低的程度高于对照组（P＜0.05）；研究组患者不良反应发生率低于对照组（P＜0.05）。结论使用前列地尔联合贝那普利治疗糖尿病肾病可降低尿蛋白的含量，不良反应发生率小。